Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...4243444546474849505152...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  A Traditional Chinese Patent Medicine ZQMT for Neovascular Age-Related Macular Degeneration: a multicenter randomized clinical trial. (Pubmed Central) -  Oct 8, 2019   
    The combinatory therapy of ranibizumab and traditional Chinese patent medicine ZQMT had equivalent effects on visual acuity improvement and safety profiles as the ranibizumab treatment alone. Ranibizumab injections coupled with ZQMT offer therapeutic advantages in terms of reduction of retinal lesions and eases the financial burden of patients undergoing treatment by reducing the frequency of necessary ranibizumab injections.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Trial completion date, HEOR:  Protocol T: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) -  Oct 8, 2019   
    P3,  N=660, Completed, 
    Ranibizumab injections coupled with ZQMT offer therapeutic advantages in terms of reduction of retinal lesions and eases the financial burden of patients undergoing treatment by reducing the frequency of necessary ranibizumab injections. Trial completion date: Oct 2018 --> Apr 2019 | Active, not recruiting --> Completed
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. (Pubmed Central) -  Oct 4, 2019   
    Preincubation with anti-VEGF drugs can alter the miRNA expression profile in response to H2O2-induced oxidative stress, and these drugs may have epigenetic effects. In patients with recurrent ME secondary to CRVO, there was improvement in BCVA and CFT in all groups, although patients treated with aflibercept showed a trend toward better anatomical outcomes decreased need for recurrent injections.
  • ||||||||||  Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  ZEBRA: Ziv-aflibercept Efficacy in Better Regulating AMD (clinicaltrials.gov) -  Oct 2, 2019   
    P2,  N=62, Active, not recruiting, 
    In patients with recurrent ME secondary to CRVO, there was improvement in BCVA and CFT in all groups, although patients treated with aflibercept showed a trend toward better anatomical outcomes decreased need for recurrent injections. Recruiting --> Active, not recruiting | N=100 --> 62 | Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Jul 2020
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. (Pubmed Central) -  Sep 30, 2019   
    This overview of reviews and meta-analyses suggest that anti-VEGF treatments do not increase the risk of systemic adverse events, but that caution might be advisable in older patients with age-related macular degeneration who may be at higher risk of hemorrhagic events when receiving ranibizumab. Ranibizumab was effective in the treatment of macular edema secondary to branch retinal vein occlusion in both visual and anatomical outcomes; however, dexamethasone implant was effective only in anatomical outcomes.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  In vivo antivascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTR-proNGF pathway. (Pubmed Central) -  Sep 28, 2019   
    In this study, we demonstrated that anterior chamber injection (IC), but not IVT injection of two different anti-VEGF agents, aflibercept and ranibizumab, affects rabbit corneal endothelium in terms of survival and apoptosis and is associated with changes in endothelial expression of NGF precursor (proNGF) and p75 neurotrophin receptor (p75NTR) receptor. We observed an increase in corneal endothelial cell incorporation of trypan blue and expression of cleaved-caspase 3 (c-Casp3), p75NTR, and RhoA after IC injection of both anti-VEGF drugs when compared with the vehicle...Aflibercept also mediated a significant increase in endothelial expression of proNGF when compared with the vehicle. In line with these data, IC administration of both anti-VEGF agents induced the activation of apoptotic signals in endothelial cells, including an increase in c-Casp3, decrease in Bad Ser 112 phosphorylation, and unbalance of AKT phosphorylation. These results demonstrated that administration of anti-VEGF in the anterior chamber of rabbit affects endothelial cell survival by inducing apoptosis through alteration of NGF pathway.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Сombined surgical treatment for diabetic macular edema (Room 353) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2266;    
    Purpose: To evaluate the results of treatment of diabetic macular edema using a combined vitrectomy / ranibizumab and only vitrectomy as monotherapy... Combination therapy including PPV with peeling epiretinal membrane and ILM peeling in combination with IVR demonstrates the best anatomical and functional results, in particular: the improvement of visual acuity and decrease of the central area of the retina thickness in patients with diabetic macular edema and epiretinal membrane.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / Allergan, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Ozurdex in macular oedema associated with retinal vein occlusion - real world 3 year data from Eastbourne (Room 353) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2257;    
    The outcomes from this study show that visual improvements may not be sustained for all patients, but there is a low risk of serious complications in our study group. Further Ozurdex may be considered as a adjunct or treatment in place of Anti-VEGF treatment for macular oedema secondary to retinal vein occlusion, although the natural history of the disease may limit visual improvements more in the long term.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema (Room 353) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2254;    
    Effects of ranibizumab on the VA of patients with RVO after 12 months from this interim analysis of the PACIFIC study will be presented. We can state through this study that the treatment of diabetic macular edema with anti-VEGF associated with corticosteroid has a greater benefit than the treatment with these single drugs, shown by optical coherence tomography.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Treatment of diabetic macular oedema: real world outcomes from a dedicated UK injection unit (Amphitheatre Havane) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2114;    
    However, the study highlighted an insufficient consideration of additional intravitreal steroid use in patients who were not responding to anti-VEGF treatment, and a tendency to continue injecting ‘non-responders’. Recognising and changing these practices could reduce the number of injections given, both reducing the cost and burden on the service as well as increasing patient compliance with a reduced number of appointments.The majority of patients (91%) did not attend the recommended 6 monthly outpatient review in diabetic eye clinic which is where additional risk factors are monitored and general advice can be given to help in the overall management of diabetic eye disease.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    CANTREAT study 24-month results: the ability to extend treatment and associated visual outcomes in the treat and extend group (Room: 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2091;    
    This analysis of nAMD patients treated with ranibizumab showed that BCVA improvement was similar between the group that could not be extended beyond 6 weeks and the group that could be extended from 10 to the maximum 12 weeks allowed per protocol. These data suggest that in treatment-naïve nAMD patients, after 24-months, even those patients who could not be extended achieved clinically meaningful improvements in BCVA.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Analysis of the relationship between anatomic control and visual acuity outcomes with anti-VEGF therapy: a post-hoc analysis of catt study data (Amphitheatre Havane) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2062;    
    The findings suggest that prolonged exposure to excess macular fluid during the first year of anti-VEGF treatment, as signified by a higher cumulative average central retinal thickness with an IRF component or a greater proportion of time with IRF present, results in sub-optimal BCVA improvement, after controlling for age, gender, baseline BCVA and retinal thickness. The ability to achieve and sustain a dry retina and adhere to a treatment regimen that provides consistent anatomic control remain key treatment considerations in nAMD.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    A three-year follow-up report on different treatment schemes for retinopathy of prematurity in stage 4A (Room 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1871;    
    For patients with stage 4A ROP scleral cerclage combined with retinal laser photocoagulation or scleral cerclage combined with intravitreal injection of ranibizumab can effectively relieve retinal proliferation, restore retinal activity, inhibit neovascularization.The retina was successfully reattached and the further development of the lesion was prevented. Axial growth appeared in both eyes.the peripheral retina of the eyes treated with laser was obviously destroyed,ametropia were significantly changed compared with the contralateral eyes.Therefore, anti-vascular therapy has achieved better results in this case.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Treatment of diabetic macular oedema: real world outcomes from a dedicated UK injection unit (Amphitheatre Havane) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1863;    
    However, the study highlighted an insufficient consideration of additional intravitreal steroid use in patients who were not responding to anti-VEGF treatment, and a tendency to continue injecting ‘non-responders’. Recognising and changing these practices could reduce the number of injections given, both reducing the cost and burden on the service as well as increasing patient compliance with a reduced number of appointments.The majority of patients (91%) did not attend the recommended 6 monthly outpatient review in diabetic eye clinic which is where additional risk factors are monitored and general advice can be given to help in the overall management of diabetic eye disease.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    CANTREAT study 24-month results: the ability to extend treatment and associated visual outcomes in the treat and extend group (Room 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1841;    
    This analysis of nAMD patients treated with ranibizumab showed that BCVA improvement was similar between the group that could not be extended beyond 6 weeks and the group that could be extended from 10 to the maximum 12 weeks allowed per protocol. These data suggest that in treatment-naïve nAMD patients, after 24-months, even those patients who could not be extended achieved clinically meaningful improvements in BCVA.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Prognostic factors of functional response in major branch retinal vein occlusion (Amphitheatre Havane) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1774;    
    BRVO can be divided in mBRVO (occlusion of one of the major branch retinal vein) and macular BRVO (occlusion of the macular venules). It is reported that the majority of mBRVO occurs in the superior temporal quadrant.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Real-world use of intravitreal aflibercept injections in diabetic macular edema: 1-year interim results of APOLLON (Amphitheatre Havane) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1769;    
    P=N/A
    Of those previously treated, 44 had prior treatment with ranibizumab and 41 with photocoagulation laser... This 12-month interim analysis of the APOLLON study showed that IVT-AFL was associated with functional and anatomical improvements in both treatment-naïve and previously treated patients with DME in routine clinical practice in France.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Long-term outcomes of intravitreal anti-VEGF treatment for choroidal neovascularization secondary to pseudoxanthoma elasticum (Arlequin) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1761;    
    Eyes were treated on pro re nata basis: 36 eyes with bevacizumab, 2 eyes with ranibizumab, 1 eye with aflibercept and 3 eyes with a combination of different anti-VEGF agents. Treatment with anti-VEGF injections can stabilise vision in eyes with CNV secondary to pseudoxanthoma elasticum but prolonged monitoring for recurrence and multiple recurrences are common with this disease entity.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Data analysis of itravitreal therapy in wet age-related macular degeneration through the fight retinal blindness platform (Arlequin) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1754;    
    This online platform allows us to audit our results in neovascular-AMD, and permits data extraction and data comparison on real life medical practice. It automatically generates graphics with visual acuity, number of intravitreal injections, drug injected, charachteristics and activity of the neovascular-AMD on each visit.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Central retinal thickness measurements in exudative age-related macular degeneration refractory to anti-vegf: influence of time parameters (Amphitheatre Havane (Level 3)) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1732;    
    The significant correlation between CRT and treatment initiation corresponds with slowly progressive CRT change over time, either associated with progressive increase of CRT / fluid quantity (40%, positive correlation) or progressive decrease of CRT / fluid quantity (60%, negative correlation), implying an influence of time alone in the CRT in a large subset (63%) of refractory nAMD cases. In addition, the time interval from last injection influences the CRT measure in more than half of the patients (58%).
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Macular atrophy in Anti-VEGF Treated Neo-vascular AMD: incidence and risk factors (Amphitheatre Havane (Level 3)) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1729;    
    We found that the presence of subretinal fluid at baseline seems to be protective for the development of cRORA. We also concluded that incidence of cORA is associated with a higher number of injections, independently of the drug type.